IR BioSciences Holdings, Inc. (IRBS.OB) Subsidiary Explores Possibility of Partnership with Archimedes Development Ltd.
QualityStocks (August 26th, 2009) Writes:
ImmuneRegen BioSciences, Inc., a wholly owned subsidiary of IR BioSciences Holdings, Inc., announced this morning that it has executed a Material Transfer Agreement (MTA) with Archimedes Development Limited. This collaboration enables the companies to identify possible synergies between their technology platforms.
“Multiple studies in different model systems have shown that Homspera can protect experimental animals and enhance their immune responses to vaccine-delivered antigens, DNA-encoded viral proteins or tumor antigens, as well as provide protection in our anthrax and influenza therapeutic studies,” stated Hal Siegel, Ph.D., ImmuneRegen’s Vice President and Chief Scientific Officer.
He continued, “In addition to these findings in animals where Homspera has been administered intranasally as a liquid, inhaled or injected under the skin, we have shown in laboratory studies that Homspera can stimulate blood-forming stem cells to produce more white blood cell precursors, particularly those for granulocytes and macrophages, mature blood cells which play a significant role in
...Alan Smith, anthrax;, Archimedes Development Limited, Hal Siegel, HIV/AIDS, ImmuneRegen BioSciences Inc., Influenza, intestinal diseases, IR BioSciences Holdings Inc.;, leader, Market Commentary, mass vaccination, model systems, owned subsidiary, pandemic influenza, Small & Micro Cap, Stem Cells, Technology Platforms, tumor, vaccination, Vaccines, Vice President and Chief Scientific Officer, Vice President of Research & Development


![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/gold/t24_au_en_usoz_2.gif)
![[Most Recent Quotes from www.kitco.com]](http://www.kitconet.com/charts/metals/silver/t24_ag_en_usoz_2.gif)




